Division of Gastroenterology and Gastrointestinal Endoscopy, Vita Salute San Raffaele University, Scientific Institute San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Section of Gastroenterology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, USA.
Surg Endosc. 2018 May;32(5):2328-2339. doi: 10.1007/s00464-017-5928-8. Epub 2017 Nov 2.
Endoscopic submucosal dissection (ESD) and hybrid-ESD techniques are treatment modalities for colorectal neoplasia, although mostly used in the Eastern hemisphere. Only few data on ESD for colorectal neoplasia have been published in the West. We report the outcomes of colorectal ESD and hybrid ESD in a single Italian center.
We retrospectively evaluated the outcomes of all ESD and hybrid-ESD procedures for colorectal neoplasia performed over the first 2-year experience from a prospectively recorded database. Neuroendocrine tumors and adenocarcinoma with submucosal infiltration through the submucosal (SM) 2 layer or deeper were excluded. The primary outcome was the recurrence rate at the 6- to 12-month follow-up.
Fifty-two patients were included in the study, of which 23 underwent ESD and 29 hybrid ESD. The mean lesion sizes for ESD and hybrid ESD were similar (25.8 vs. 25.4 mm, p = 0.940), while median procedure length was significantly longer for ESD (120 vs. 60 min, p < 0.001). ESD and hybrid ESD yielded similar en-bloc resection rate (82.6 vs. 82.8%) and R0 resection rate (34.8 vs. 31%). ESD had a lower neoplasia recurrence rate than hybrid ESD (11.7 vs. 20%) and a lower bleeding rate (0 vs. 8.7%). One perforation occurred in the hybrid-ESD cohort and two perforations in the ESD cohort, of which one required surgical intervention. Non-recurrence at follow-up was associated with R0 status, en-bloc resection, and lesion size ≤ 20 mm.
Our outcomes are comparable with other studies in Western series. Studies addressing the cost effectiveness of ESD and comparing its long-term outcome with endoscopic mucosal resection in the West are needed.
内镜黏膜下剥离术(ESD)和杂交 ESD 技术是结直肠肿瘤的治疗方法,尽管主要在东亚使用。西方仅发表了少数关于结直肠肿瘤 ESD 的数据。我们报告了一家意大利单中心的结直肠 ESD 和杂交 ESD 的结果。
我们从前瞻性记录的数据库中回顾性评估了首例 2 年经验中所有用于结直肠肿瘤的 ESD 和杂交 ESD 手术的结果。排除神经内分泌肿瘤和黏膜下浸润穿过黏膜(SM)2 层或更深的腺癌。主要结果是 6-12 个月随访时的复发率。
52 例患者纳入研究,其中 23 例行 ESD,29 例行杂交 ESD。ESD 和杂交 ESD 的平均病变大小相似(25.8 与 25.4mm,p=0.940),而 ESD 的中位手术时间明显更长(120 与 60min,p<0.001)。ESD 和杂交 ESD 的整块切除率(82.6%与 82.8%)和 R0 切除率(34.8%与 31%)相似。ESD 的肿瘤复发率低于杂交 ESD(11.7%与 20%),出血率也较低(0 与 8.7%)。杂交 ESD 组发生 1 例穿孔,ESD 组发生 2 例穿孔,其中 1 例需要手术干预。随访时无复发与 R0 状态、整块切除和病变大小≤20mm 有关。
我们的结果与西方系列的其他研究相似。需要进行研究来确定 ESD 的成本效益,并将其与西方的内镜黏膜切除术的长期结果进行比较。